Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW extension: long‑term follow‑up of ranibizumab vs laser in retinopathy of prematurity
2014-004048-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranibizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by Novartis. Primary endpoint: Visual acuity in the better-seeing eye. Started Mar 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2014-004048-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004048-36.